Legend Biotech (LEGN) Stock Hits New Lows: Oversold CAR-T Leader or Long-Term Opportunity?
As of December 9, 2025, shares of Legend Biotech Corporation (NASDAQ: LEGN) are under heavy pressure even as the company posts strong growth from its flagship CAR-T therapy, CARVYKTI. Here’s a deep dive into the latest news, forecasts, analyst calls and technical signals that are driving sentiment around Legend Biotech stock today. Where Legend Biotech Stock Trades Now Legend Biotech’s American Depositary Shares (ADS) were recently trading around $24.1, down roughly 8% on the day and hovering near fresh 52-week lows. Benzinga On December 9, 2025, the stock: A company news brief from Investing.com highlighted that Legend Biotech shares hit